XPAR
BOI
Market cap356mUSD
Oct 09, Last price
17.60EUR
1D
-2.66%
1Q
-32.97%
Jan 2017
-78.26%
Name
Boiron SA
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Boiron S.A., founded in Messimy, France, in 1932, is a pharmaceutical company dedicated to the production and global sale of homeopathic medicines. Its market presence spans France, the broader European continent, North America, and numerous international territories. The company's offerings range from non-proprietary and proprietary formulations to a variety of branded homeopathic treatments. Among its prominent branded homeopathic products are Oscillococcinum, targeting influenza symptoms like fever, chills, headaches, and body aches; Stodal and Stodaline, developed for cough relief; Arnigel, for the localized adjunctive treatment of benign trauma without open wounds; Camilia, designed to alleviate teething problems in babies; and Sédatif PC, prescribed for anxiety, emotional distress, and minor sleep disorders. Additional homeopathic solutions include Coryzalia, for cold symptoms and rhinitis; Homéoptic, to soothe eye discomfort and irritation in all age groups; and Homéovox, for vocal disturbances. Beyond its core homeopathic range, Boiron also provides a selection of other health and wellness products. These encompass dietary supplements; the Dermoplasmine series (stick, balm, and mousse) for addressing dry lips and skin; Mag' Nuit, a formulation to assist with falling asleep; Arnitrosium, for joint pain; Castor Equi Boiron ointment, for cracked skin treatment; and Storinyl, a syrup to manage colds. Furthermore, the company offers herbal medicines, such as Canephron, which promotes diuresis and improved urinary elimination, alongside moisturizing baby milk and medical devices, including a range of COVID-19 self-tests and rapid antigenic tests. Boiron's products reach consumers through a comprehensive distribution network comprising dedicated centers, pharmacies, pharmacy chains, wholesalers, grocery stores, drugstores, health food stores, and various online retail channels.
Related entities
Parent
SOCIETE DE DEVELOPPEMENT ET DE VALORISATION-SODEVA
Subsidiaries
BOIRON LABORATORIES PRIVATE LIMITED
Key people
Anabelle Flory-Boiron
Non-Executive Chairman of the Board · since 2024
Thierry Boiron
Executive Director · since 2025
Pascal Houdayer
Chief Executive Officer, Executive Director · since 2025
Benjamin Boiron
Non-Executive Director · since 2023
Laurence Boiron
Non-Executive Director - Permanent Representative of Boiron Development · since 2023
Christine Boyer-Boiron
Non-Executive Director · since 2003
Stephanie Chesnot
Non-Executive Director · since 2010
Jean-francois Henaux
Non-Executive Director - Employees Representative · since 2021
Virginie Heurtaut
Non-Executive Director · since 2013
Evis Hursever
Non-Executive Director - Permanent Representative of Domino Fund 3 Holdco GP LLC · since 2023
Sylvain Mossaz
Non-Executive Director - Employees Representative · since 2020
Emmanuel Vigne
Non-Executive Director - Employee Representative · since 2024
Gregory Walter
Non-Executive Director - Representative of Shareholder Employees · since 2017
Non-Executive Independent Director · since 2021
Philippe Brown
Non-Executive Independent Director - Permanent Representative of FIDENTIS · since 2024
Jean- Marc Chalot
Non-Executive Independent Director · since 2022
Headquarters & legal address
2 AVENUE DE L'OUEST LYONNAIS
MESSIMY 69510
FR
MESSIMY 69510
FR
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||